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Acquiring timely information on an individual’s health and related risks through screening 
tests and diagnoses could potentially affect patients’ behaviour and reduce avoidable health 
care use and associated costs (WHO, 2016; Liang et al., 2019). Recent medical studies find 
that the diagnosis of different types of cancers may affect positively the lifestyle (as measured 
by smoking, drinking, dietary changes and exercise) of a minority of older male individuals 
(Jazieh et al., 2006) and that a significant proportion of patients diagnosed with lung or 
head/neck cancer continue smoking (Burris et al., 2015). Yet, such medical evidence appears 
to mainly focus on cancer diagnoses and is often based on limited cross-sectional samples as 
well as simple statistical correlations. Hence, whether a diagnosis might have a causal impact 
on lifestyle behaviours remains an open empirical question.  
While the economics literature on the effectiveness of different types of broad health 
information campaigns is wide and increasingly exploits causal inference methods (e.g. Brown 
and Schrader, 1990; Chern at al., 1995; Kim and Chern, 1999; Roosen et al., 2009; Alleis et 
al., 2015; Fichera and von Hinke, 2020), only a handful of recent economic studies have so far 
explored the causal impact of a diagnosis on lifestyle behaviours (Zhao et al., 2013; Kim et al., 
2019; Gaggero, 2020). Zhao et al. (2013) employ a regression discontinuity design (RDD) on 
data from the China Health and Nutrition Survey (CHNS) to investigate the impact of a 
hypertension diagnosis on several health outcomes. They find that individuals respond to a 
hypertension diagnosis by substantially decreasing their fat intake with the effect being 
especially relevant among wealthier individuals. Similarly, Kim et al. (2019) use a RDD on 
data drawn from the Korea’s National Health Screening Program on type-2 diabetes mellitus 
(T2DM); hyperlipidaemia (high cholesterol); and obesity diagnoses. Their findings suggest 
overall limited effects of disease-related risk information if provided in isolation. However, 
they also find that individuals classified as high risk for diabetes who are prompted for a second 
visit exhibit reductions in waist circumference in the short-run.1 Moreover, exploiting a RDD 
on a sample of individuals aged 50 years and above, Gaggero (2020) provides evidence of a 
short-term reduction in BMI and waist circumference following a T2DM diagnosis. Hence, 
results on the causal impact of a diagnosis on lifestyle behaviours appear to be mixed. 
Furthermore, all these studies appear to focus on short-term effects. 
                                                 
1 Though not based on a formal diagnosis, Cook (2018) also exploits an RDD to estimate the role of 
personalised weight information on weight change and finds only a moderate impact concentrated among the 
“very overweight” with higher income.  
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  In addition, the broader correlational literature on the effects of a T2DM diagnosis on 
health-behaviours also appear to be generally inconclusive. For instance, Chong et al. (2017) 
suggest a weak association between lifestyle changes and a T2DM diagnosis while Seuring et 
al. (2020) find some contradicting results among women (decreased BMI but also increased 
hypertension and reduced physical activity). Relevant to this paper, in one of the very few 
correlational studies exploring long-term effects, Slade (2012) suggests that the association 
between a T2DM diagnosis and changes in health-behaviours tend to disappear over time with 
evidence of recidivism (weight gain and decreased physical exercise) two years after a 
diagnosis.  
The main objective of this paper is to identify short- and long-term causal impacts of a 
diagnosis of T2DM on key modifiable lifestyle behaviours, including obesity, smoking and 
alcohol consumption. We focus on T2DM as it is among the most widespread chronic 
conditions worldwide currently affecting 462 million individuals (6.28% of the world’s 
population); it is the ninth leading cause of death globally; and its burden of disease is projected 
to raise at an increasingly faster pace in both developing and developed countries (Khan et al., 
2020).  
We employ a fuzzy RDD on comprehensive longitudinal administrative data from Spain 
and exploit the exogenous cut-off of an established biomarker used for T2DM diagnoses, 
namely glycated haemoglobin (HbA1c). We estimate the impact of a T2DM diagnosis on 
clinically measured BMI, quitting smoking and quitting drinking both short-term (within one 
year from the diagnosis) and long-term (up to three years after the diagnosis). 
We find a statistically significant and substantial reduction in BMI following a T2DM 
diagnosis. This effect appears to be stronger among obese individuals and those diagnosed with 
depression. Differently from previous studies, we also provide evidence of statistically 
significant long-term impacts of a T2DM diagnosis on weight even after three years since the 
diagnosis. Moreover, younger individuals, those still in the labour market and who are 
healthier, present increased short-term probabilities of quitting smoking. Our results appear to 
be consistent throughout alternative parametric and non-parametric specifications with varying 
bandwidths and further robustness checks. 
This paper contributes to the literature in several important ways. First, our findings are 
produced using uniquely suited panel data, including a reliable biomarker used as the running 
variable in our RDD approach, and a number of clinically measured anthropometric and health- 
related variables. Importantly, such data allows for the possibility of identifying long-term 
effects as well as heterogeneity in the effects of a diagnosis.  Secondly, we focus our empirical 
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exploration on individuals affected by T2DM, one of the most prevalent chronic conditions 
worldwide. We do so by using a large sample of individuals drawn from the general population 
in Spain, a European country with one of the highest rates of metabolic diseases (Rojo-Martinez 
et al., 2020). Thirdly and differently from previous studies on the impact of a T2DM diagnosis 
employing a sharp RDD, our fuzzy RDD approach explicitly accounts for the possibility that 
a T2DM diagnosis may not be exclusively based on the value of a single biomarker but on a 
broader set of patients’ characteristics. That is, our approach allows to more realistically take 
into account that medical doctors could inform their diagnoses using a range of information, 
including family history and the presence of further health conditions. Fourthly, whereas recent 
studies in the area (e.g. Kim et al., 2019; Gaggero, 2020) use an objective measure of blood 
sugar (i.e. Fasting Plasma Glucose, FPG), such measure is sensitive to short-term lifestyle 
changes and tend to underestimate diabetes prevalence. In this study, we employ a more 
reliable biomarker (i.e. glycated haemoglobin, HbA1c) which does not suffer from these 
limitations (American Diabetes Association, 2020).  
Overall, this study provides novel causal evidence on the short- and long-term impacts of a 
T2DM diagnosis by employing a fuzzy RDD on rich longitudinal administrative data. 
Accordingly, this contributes directly to and extends the growing economics literature on the 
impact of health information on lifestyle behaviours among people with chronic conditions. 
 
2. Data and institutional setting  
2.1 Data  
We make use of rich individual-level longitudinal data drawn from administrative records 
of patients followed over seven consecutive years (2004-2010) in six primary care centres and 
two hospitals in the municipality of Badalona (north-east of Barcelona, Spain), providing care 
to a population of around 104,000 individuals. Our sample includes patients aged 16+ who had 
at least one contact with the health care system between 1 January 2004 and 31 December 2010 
and were assigned to one of such healthcare centres.2 The dataset includes information about 
each patient’s clinical measurements of height and weight; chronic conditions and other 
diagnosed diseases, according to the International Classification of Primary Care, second 
edition (ICPC-2); lifestyles (smoking and drinking); date of admission and discharge; type of 
                                                 
2 We exclude from the analysis patients transferred or moved to other centres and those from other areas or 
regions. However, since movements across centres are rare events, this is unlikely to have a significant impact on 
our results. 
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health care professional(s) contacted and reasons of visit. Moreover, the dataset contains 
patients’ age; gender; employment status (active versus non-active); as well as immigration 
status (defined by the place of birth, i.e. European Union, EU, versus non-EU) and current 
residence. While the initial sample includes a total of 123,453 patients, given the purpose of 
our analysis we restrict our estimating sample to 13,971 individuals with at least one biomarker 
measurement per year.  
 
2.2. Key Variables  
Our analysis focuses on the impact of a T2DM diagnosis on modifiable lifestyle behaviours 
(weight, alcohol and tobacco consumption), while accounting for a number of relevant health-
related and sociodemographic observed variables. Our key treatment variable is a binary 
indicator based on a physician’s diagnosis of type-2 diabetes reported using the corresponding 
ICPC-2 code. We couple this information with the one provided by a biomarker, glycated 
haemoglobin (HbA1c), which provides an accurate measure of glucose concentration over the 
previous 8-12 weeks (Goldstein et al. 2004; IEC, 2009; Lyons and Basu, 2012). HbA1c 
measurements are endorsed by the International Expert Committee (IEC) and the American 
Diabetes Association (ADA) as they appear to be more reliable if compared to other measures 
of blood sugar such as the ones based on Fasting Plasma Glucose (FPG) (IEC, 20; ADA, 2010, 
2020; Ho-Pham et al., 2017). For instance, FPG tests have a limited time validity; are sensitive 
to short-term lifestyle changes and stress; and have been found to underestimate the prevalence 
of diabetes.3  
Our outcomes of interest are three lifestyle behaviours whose improvement monitored as 
part of the standard treatment for T2DM prescribed by physicians: (1) body mass index (BMI); 
(2) smoking; and (3) alcohol consumption.4 Importantly, our data includes clinically measured 
BMI, thus avoiding potential issues related to measurement error and reporting bias.  Smoking 
and alcohol consumption are binary variables defining whether an individual is currently a 
smoker and drinks alcohol, respectively. These are also derived from patients’ clinical records 
as reported by the physician (and thus they are not simply self-reported by patients). Since we 
can only observe smoking and drinking at the extensive margin, our interest is on the impact 
of a T2DM diagnosis on quitting smoking and quitting alcohol consumption.  
 
                                                 
3 This is also a distinctive advantage in terms of the identification within our RDD as it is highly unlikely for 
patients to manipulate HbA1c scores, i.e. our running variable (see section 3 as well). 
4 BMI is defined as weight divided by the square of height. 
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2.3 Institutional setting  
Our data are drawn from medical records of GP practices and hospitals based in Spain, an 
EU country with a universal health care system free at the point of delivery with the exception 
of pharmaceuticals, which may require co-payment (Bernal et al., 2018). In this setting, 
physicians follow standard national medical guidelines for managing patients with T2DM 
(Mata et al., 2013) where the threshold value of HbA1c ≥ 6.5 percent is used as the main criteria 
for a T2DM diagnosis.5 However, it is worth noting that realistically medical doctors may not 
base their diagnosis exclusively on HbA1c values and could look at broader patients’ 
characteristics, including family history around T2DM and whether they present other 
metabolic conditions, such as hypertension or dyslipidaemia (i.e. an abnormal amount of lipids 
in the blood, including triglycerides and cholesterol). Ultimately, this may imply that some 
patients with several metabolic conditions and a value of HbA1c just below 6.5 percent may 
be diagnosed with T2DM. We account for this in our empirical approach by both employing a 
fuzzy rather than a sharp RDD, allowing the discontinuity driven by a T2DM diagnosis not to 
depend only on the value of our running variable (HbA1c), and including general practitioners 
(GP) fixed effects.6  
 
3. Econometric Methods   
3.1 Regression Discontinuity Design 
Our empirical strategy exploits the exogenous cut-off value in the diagnosis of T2DM 
provided by the biomarker glycated haemoglobin (HbA1c) via a Regression Discontinuity 
Design (RDD). This allows us identifying the causal impact of a T2DM diagnosis on our 
outcomes of interest, i.e. lifestyle behaviours.     
Specifically, drawing from the potential outcomes framework outlined by Rubin (1974), let 
𝐷𝑖 be a binary indicator that equals unity for patients diagnosed with T2DM and zero otherwise. 
Let the pair {𝑌𝑖
1, 𝑌𝑖
0} denote the potential outcomes individual 𝑖 would obtain in case he/she 
                                                 
5 Note that blood sugar levels ranging between 5.7% ≤ HbA1c ≤ 6.4% would define a prediabetes condition, 
i.e. blood glucose levels would be high, but not high enough to prompt a diabetes diagnosis.  
6 Note that upon being diagnosed with T2DM, patients are recommended a series of follow up visits where 
weight, height and HbA1c measurements are performed. This normally happens during an initial visit as well as 
further visits at 6 and 12 months since the diagnosis. Lifestyle changes are then monitored during follow up visits 
(Mata et al., 2013).  
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does or does not receive a T2DM diagnosis, respectively. The observed outcome, 𝑌𝑖, can be 
written as follows: 
 𝑌𝑖 = 𝑌𝑖
0 + (𝑌𝑖
1 − 𝑌𝑖
0)𝐷𝑖,   (1) 
 
where (𝑌𝑖
1 −  𝑌𝑖
0), the difference between the two potential outcomes, is defined as the 
causal effect of a T2DM diagnosis for individual 𝑖. Since, at any moment, an individual can 
only be either diagnosed or not, we cannot observe the effect of T2DM diagnosis for each 
individual (Holland, 1986). Indeed, a naïve comparison between diagnosed versus undiagnosed 
individuals, would only provide a biased estimate of the true causal effect of the diagnosis. To 
illustrate this, we can show that the difference in outcomes between individuals with and 
without a T2DM diagnosis can be written as: 
 
 𝐸[𝑌𝑖|𝐷𝑖 = 1] - 𝐸[𝑌𝑖|𝐷𝑖 = 0] = 𝐸[𝑌𝑖
1 − 𝑌𝑖
0|𝐷𝑖 = 1] +  𝐸[𝑌𝑖
0|𝐷𝑖 = 1]- 𝐸[𝑌𝑖




0|𝐷𝑖 = 1] is the causal effect of interest (specifically, the average treatment 
effect on the treated, ATT), and the term 𝐸[𝑌𝑖
0|𝐷𝑖 = 1]- 𝐸[𝑌𝑖
0|𝐷𝑖 = 0] represents selection 
bias, which in this case accounts for baseline differences between the two groups (i.e., 
diagnosed vs non-diagnosed individuals).  
In this study, we exploit the fact that the probability of being diagnosed with T2DM changes 
discontinuously as a function of the value of the biomarker HbA1c being above or below a pre-
determined cut-off and use a RDD to address selection bias. This type of design was first 
introduced by Thistlethwaite and Campbell (1960) and then formalised by Hahn et al. (2001), 
who derived the necessary conditions for the identification of causal effects. Let us define the 
pre-determined cut-off point, ℎ0, and let the running variable of interest,  ℎ𝑖,𝑡, be the normalised 
HbA1c at time 𝑡, namely ℎ𝑖,𝑡 = (𝐻𝑏𝐴1𝑐𝑖𝑡 − ℎ0). The main idea behind RDD is that individuals 
just above or below the pre-identified cut-off point are otherwise identical but in the probability 
of being diagnosed, and hence selection bias around the cut-off should disappear (e.g. Imbens 
and Lemieux, 2008; van der Klaauw, 2008; Lee and Lemieux, 2010; Moscoe et al., 2015). 
In general, there are two types of RDD: the sharp and the fuzzy design (see Trochim, 1984). 
A sharp design assumes that treatment assignment is a deterministic function of the running 
variable whereas in a fuzzy design treatment assignment is assumed to be a stochastic function 
of the running variable. In our case, we would use the sharp design if the T2DM diagnosis 
would depend solely on the running variable, ℎ𝑖,𝑡 , being above or below the pre-determined 
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threshold value. However, as mentioned in Section 2, because a T2DM diagnosis is ultimately 
at the discretion of the physician, and hence may depend also on other patients’ characteristics, 
a fuzzy design is deemed to be more appropriate in this case.  
Formally, let us define an indicator variable 𝐴𝑏𝑜𝑣𝑒𝑖,𝑡 = 1(ℎ𝑖,𝑡 ≥ 0), which takes the value 
of unity for patients with values of the HbA1c greater than or equal to the predetermined cut-
off level. Then, we can write: 
 
Pr{𝐷𝑖,𝑡 = 1} = {
𝑓1(ℎ𝑖,𝑡),            𝑖𝑓  𝐴𝑏𝑜𝑣𝑒𝑖,𝑡 = 1
𝑓0(ℎ𝑖,𝑡),             𝑖𝑓  𝐴𝑏𝑜𝑣𝑒𝑖,𝑡 = 0
; (3) 
 
where, owing to the discontinuity at the cut-off point, 𝑓1(ℎ𝑖,𝑡)  ≠ 𝑓0(ℎ𝑖,𝑡). In the spirit of 
Hahn et al. (2001), a regression framework for a fuzzy RDD is offered by the instrumental 
variable approach. Accordingly, we estimate a version of Equation (4) on a series of 
outcomes of interest as follows: 
 
 𝑌𝑖,𝑡+1 = 𝑔(ℎ𝑖,𝑡) + 𝛽𝐷𝑖,𝑡 +  𝑿𝒊,𝒕
′ 𝛾 + 𝜀𝑖,𝑡, (4) 
 
where we use 𝐴𝑏𝑜𝑣𝑒𝑖,𝑡 as the instrument for the T2DM diagnosis, 𝐷𝑖: 
 
 𝐷𝑖,𝑡 = 𝑓(ℎ𝑖,𝑡) + 𝜌𝐴𝑏𝑜𝑣𝑒𝑖,𝑡 + 𝑿𝒊,𝒕
′ Ω + 𝜖𝑖,𝑡. (5) 
 
where 𝑌𝑖.𝑡+1 denotes the outcome of interest and captures lifestyle behaviours at time 𝑡 + 1. 
Functions 𝑔(. ) and 𝑓(. ) are flexible polynomials of the running variable, which are allowed to 
vary around the cut-off.7 𝛽 is the main parameter of interest which, under the additional 
assumption of monotonicity, represents the local average treatment effect (LATE) of the T2DM 
diagnosis among compliers around the cut-off. These are the patients whose T2DM diagnosis 
is actually affected by the HbA1c value being above or below the cut-off. 𝑿𝒊𝒕
′  is a set of pre-
diagnosis controls whereas 𝛾 and Ω are their associated vectors of parameters. These include 
patients’ demographic characteristics, such as age and gender; a set of dummy variables to 
account for employment status (active vs non-active); marital status (living vs not living alone); 
and immigration status (as there is evidence suggesting systematic differences in lifestyle 
                                                 
7 In practice, this is done by interacting each polynomial with the assignment indicator.  
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behaviours among the immigrant populations, e.g. Carrasco-Garrido et al., 2007). We also 
account for pre-existing health conditions (hypertension and dyslipidaemia) and time elapsed 
from the diagnosis. We follow Lee and Lemieux (2010) and in order to reduce sampling error, 
we include covariates defining baseline (i.e. time 𝑡) lifestyle behaviours. 
Additionally, our econometric specifications included time-, health area- and GP fixed-
effects (FE). In particular, the inclusion of GP FE allows us controlling for systematic 
differences across physicians that might affect both a T2DM diagnosis and health outcomes. 
For example, some GPs may be stricter and diagnose patients with T2DM as soon as the HbA1c 
approaches the pre-determined cut-off, while some others may be more lenient and only 
officially diagnose T2DM when the HbA1c value reaches higher levels. Similarly, other 
physicians may be more cautious about the use of drugs and more prone to recommend lifestyle 
changes, while others may rely mainly on pharmaceutical treatments for the management of 
T2DM. Our empirical strategy enables accounting for such differences. Finally, 𝜀𝑖,𝑡 and 𝜖𝑖,𝑡 are 
random error terms. We cluster standard errors on the running variable based on the 
recommendation of Lee and Card (2008). 
A RDD can be implemented parametrically by using all data points, both “close to” and “far 
away” from the cut-off, to estimate Equation (4). Alternatively, one could also use a non-
parametric approach (e.g. local linear regression), where Equation (4) would be estimated on a 
sample of individuals in an arbitrarily small neighbourhood around the cut-off, ℎ0, and without 
the polynomial term, 𝑔(. ). We choose the former approach to make use of the full size of 
sample, but we also explore the robustness of our results via a non-parametric estimation. 
Following the recommendations of Gelman and Imbens (2018), our preferred specification 
(baseline scenario) includes a linear polynomial of the running variable (i.e., 𝑔(. ) is assumed 
to be a linear function). However, we further test the robustness of our findings with 
polynomials of orders between 1 and 4 (see Section 4). 
 
3.2 Validity 
RDD methods such as the one employed in this study rely on the standard local continuity 
assumption typical of all RDD approaches. That is, we are assuming that patients with a HbA1c 
value just above and below the cut-off should be identical, in terms of both pre-determined 
observables and unobservables. One indirect way to test for this assumption is to show that the 
distribution of the observed baseline covariates does not change discontinuously around the 
cut-off point. Accordingly, Figure 1 displays a set of local polynomial smoothing (LPS) 
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regressions for pre-diagnosis covariates: (a) age; (b) gender; (c) employment status; (d) 
immigration status; and other potential medical conditions, such as (e) hypertension, and (f) 
dyslipidaemia.8 Figure 1 does not appear to show any significant discontinuity at the cut-off 
for any of these variables, suggesting that the continuity assumption should hold in this case. 
 
[FIGURE 1 AROUND HERE] 
 
An additional concern for the validity of our identification strategy relates to the potential 
manipulation of the running variable. McCrary (2008) shows that if individuals can 
systematically manipulate the value of the running variable in order to (or not to) receive the 
treatment, then the continuity assumptions will not hold. However, here it seems implausible 
to assume that patients would be able to manipulate their HbA1c test values and influence a 
T2DM diagnosis. In particular, since HbA1c values capture the average glucose concentration 
over the previous 8-12 weeks, in order to significantly change the value of the biomarker, 
individuals should have started to substantially change their lifestyle 8-12 weeks prior to the 
test. Although such behaviour seems unlikely, in Figure 2 we investigate this issue by 
examining whether the density function of our running variable is smoothly distributed around 
the cut-off. As expected, Figure 2 reveals no evidence of a discontinuity at the (normalised) 
cut-off.9 
 
[FIGURE 2 AROUND HERE] 
 
Finally, Table 1 reports estimates of a placebo test. This test should show a zero effect for 
the outcome of interest at values other than the pre-determined cut-off value. Indeed, results 
from our placebo test confirm that when using an alternative cut-off value of HbA1c, namely 
4.75%, estimated effects are not significantly different from zero.  
 
[TABLE 1 AROUND HERE] 
 
                                                 
8 Similar graphs can be obtained for the full set of covariates and are available upon request. 
9 A formal McCrary test for the manipulation of the assignment variable confirms this finding, with an 
estimated log difference in height of ?̂?= – 0.071 (s.e. 0.0157), failing to reject the null hypothesis of no 
discontinuity. Similarly, following Cattaneo et al. (2018) we also run a robust bias-corrected manipulation test 
based on an unrestricted inference with a local-polynomial of order 2, triangular Kernel, a Jackknife standard error 
estimator and a data-driven bandwidth selection. A manipulation test score of T = - 0.4614 (p-value of 0.6445) 
was obtained, indicating no evidence of systematic manipulation of the running variable. 
 10 
4. Results 
4.1. Sample descriptives 
Table 2 displays summary statistics of the variables used in our empirical analysis.10 In 
terms of our main outcomes of interest, the table shows that individuals in the estimating 
sample present an average BMI of around 30 (widely considered as the standard threshold for 
obesity); that 18 percent of them are current smokers, while only 3 percent report drinking 
alcohol.11 The table also reports that 67 percent of individuals in the sample have been 
diagnosed with T2DM together with an average of 3.1 years since the onset of the disease. The 
mean HbA1c value for the patients in our sample is of 6.6 percent, just above the threshold 
used to diagnose T2DM. With respect to sociodemographic characteristics, Table 2 shows an 
average age of 65; that 52 percent of the sample consists of women; and that 87, 27, and 2 
percent of the individuals in the sample are not living alone; still active in the labour market; 
and are immigrants (born outside the European Union), respectively. Additionally, the Table 
reports that 59, 53 and 18 percent of the patients are also diagnosed with hypertension, 
dyslipidaemia and depression, correspondingly.  
 
[TABLE 2 AROUND HERE] 
 
4.2 Main results 
Figure 3 presents evidence of the causal impact of a T2DM diagnosis by means of a series 
of RDD plots of the outcomes of interest as a function of the (normalised) HbA1c, our running 
variable. Interestingly, the Figure exhibits a statistically significant discontinuity at the 
normalised threshold for the BMI outcome. Specifically, the plots appear to imply that patients 
with HbA1c just above the cut-off exhibit a lower BMI value than their counterparts. However, 
the Figure does not show any significant jump with respect to smoking or drinking cessation. 
We next test the significance of these findings in a regression framework while controlling for 
a number of potential confounding factors, as specified in Equations (4) and (5). 
 
[FIGURE 3 AROUND HERE] 
                                                 
10 Summary statistics by year can be found in Table A1 of the Appendix.  
11 The low prevalence of smoking and drinking in our sample might not be entirely surprising as these are all 
individuals who have been seeking medical attention at some point during the period considered in this study. In 
addition, a large proportion of them were diagnosed with medical conditions. Hence, it is likely that these patients 
have been previously advised to change their lifestyle behaviours.  
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Table 3 reports first stage RDD estimates of a T2DM diagnosis as outlined in Equation (5) 
using different specifications. Specifically, column (1) includes estimates produced by a model 
with no covariates; column (2) adds a set of observed covariates; column (3) considers baseline 
lifestyle behaviours; column (4) includes time and area FE and, finally, column (5) adds GP 
FE (preferred specification). Estimates appear to be consistent throughout all specifications and 
show that the parameter of interest (𝜌) is positive and statistically significant. This implies that 
individuals with an HbA1c above the cut-off are significantly more likely to be diagnosed with 
T2DM. 
 
[TABLE 3 AROUND HERE] 
 
The main estimates of this paper are reported in Table 4. This Table reports the RDD impacts 
on next-year lifestyle behaviours of interest (Equation 4) based on a parametric approach. Our 
findings confirm results displayed in Figure 3 implying a statistically significant RDD estimate 
of a T2DM diagnosis on BMI. More specifically, the estimated coefficient implies that 
individuals diagnosed with T2DM exhibit a decrease of 1.013 points in their next-year BMI 
level. Interestingly, in our data a T2DM diagnosis does not appear to affect either smoking or 
drinking behaviour.12 
 
[TABLE 4 AROUND HERE] 
 
4.3 Heterogeneity Analysis 
In Tables 5-7, we investigate heterogeneous effects.13 Table 5 reports RDD estimates when 
splitting the sample by gender, age, and labour market status. The Table highlights that, with 
respect to BMI, the impact of a T2DM diagnosis is quantitatively stronger among women, 
individuals younger than 60 years of age and those active in the labour market (either employed 
or actively looking for work). Additionally, the Table shows that for patients below the age of 
                                                 
12 We also allowed for the possibility that individuals with BMI measures may not be randomly drawn from 
our sample of patients and explored the presence of a potential sample selection issue following Wooldridge 
(2010). Accordingly, we estimated probit models for each time period (wave), where the dependent variable was 
a dummy taking value 1 for not having a BMI measure and including the full set of exogenous regressors and 
produced corresponding inverse Mills ratios. These were then included in our RDD models and results produced 
using such models showed no evidence of selection bias.   
13 Due to the reduced size of the resulting estimating sample, we chose not to rely on, and thus not to report, 
heterogenous RDD estimates for quitting alcohol consumption. Results are available upon request.  
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60 and who remain active, a T2DM diagnosis increases significantly the probability of quitting 
smoking in the short-term. 
[TABLE 5 AROUND HERE] 
 
In Table 6, we investigate the differential short-term effects of a T2DM by different weight 
status, using standard BMI categories (healthy weight, 18.5≤BMI≤24.9; overweight, 
25≤BMI≤29.9; obese; BMI ≥ 30; severely obese; BMI≥35). We find the more substantial 
impact among obese patients, corresponding to a 1.2 points reduction in BMI one year after a 
T2DM diagnosis. We do not find a statistically significant short-term effect of a diagnosis on 
quitting smoking across any weight categories.  
 
[TABLE 6 AROUND HERE] 
 
Finally, in Table 7 we explore whether and to what extent the short-term impact of a T2DM 
differ by pre-existing health conditions by looking at patients with no pre-existing conditions 
versus those with hypertension, dyslipidaemia, and depression. With respect to BMI, while our 
estimates do not show a statistically significant effect of the diagnosis among individuals 
without pre-existing conditions, they do display strong and statistically significant effects for 
those with previous conditions. Interestingly, the effects on BMI are larger for patients 
previously diagnosed with depression, leading to a reduction of 1.85 points on the BMI scale.   
 
[TABLE AROUND 7 HERE] 
 
Overall, our findings suggest that, following a T2DM diagnosis, the more substantial BMI 
reductions occur among individuals with comorbidities, either obese or with pre-existing 
medical conditions. On the contrary, smoking cessation after a T2DM diagnosis is more likely 
among diagnosed patients who are younger and with no pre-existing conditions.  
 
4.4 Robustness checks  
Our results appear to be robust to a battery of further checks. Table 8 reports RDD estimates 
obtained using a non-parametric approach focusing on a small neighbourhood around the cut-
off. For comparison purposes, Panel A of Table 8 presents the benchmark RDD estimates using 
the parametric approach. From Panels B to E, we report a series of non-parametric RDD 
estimates using only observations within intervals defined at varying bandwidths around the 
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HbA1c threshold of 6.5%. Although the estimates are somewhat smaller in magnitude, the 
findings appear to confirm a statistically significant decrease in BMI following a T2DM 
diagnosis, even in a substantially smaller sample. No causal short-term impact is found for 
either smoking or alcohol cessation.  
 
[TABLE 8 AROUND HERE] 
 
Furthermore, Table 9 shows results obtained by estimating the fuzzy RDD parametrically 
using different polynomial orders, ranging from a polynomial of order 1 (Panel A or baseline 
estimate) to a polynomial of order 4 (Panel D). Once again, estimates allowing for different 
flexibility of the running variable are qualitatively the same.14 
 
[TABLE 9 AROUND HERE] 
 
Additionally, we use information about time elapsed since a T2DM diagnosis and estimate 
Equation (4) by restricting the sample to the more recently diagnosed patients, including only 
those reported to have a time since diagnosis of less than a year. Despite significantly reducing 
the sample size, we believe this analysis may provide valuable information as it explores 
whether the short-term impact of a T2DM diagnosis on lifestyle behaviours could differ among 
newly diagnosed patients (and ultimately whether the time elapsed from a diagnosis plays a 
role). Table 10 reports estimates of this exercise and shows that the estimated RDD coefficients 
are still statistically significant and similar to those reported in Table 4.  
 
[TABLE 10 AROUND HERE] 
 
 
4.5 Long-term Impacts of a T2DM Diagnosis  
Another advantage brought by the use of our longitudinal administrative dataset is that it 
allows examining both short- and long-term impacts of a T2DM diagnosis. Hence, we also 
investigate whether the observed reductions in BMI following a T2DM diagnosis are sustained 
                                                 
14 Although issues around non-random heaping in the running variable might not be a concern in our study 
(because of the accuracy in the measurement of the biomarker), we also run a robustness check around this 
following Barreca et al. (2011; 2016). As expected, an exploration of the distribution of the running variable 
reveals no evidence of heaping in the data (corresponding graphs are available upon request). 
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over time, namely 1, 2, and 3 years after the diagnosis. To do this, we estimate the following 
version of Equation (4): 
 
 𝑌𝑖,𝑡+𝑗 = 𝑔(ℎ𝑖,𝑡) + 𝛽𝐷𝑖,𝑡 +  𝑿𝒊,𝒕
′ 𝛾 + 𝜀𝑖,𝑡,     where  𝑗 = 1, 2, 3. (6) 
 
Accordingly, the estimation of model (6) implies the use of at least four consecutive BMI 
measurements.15 Results reported in Table 11 suggest that the estimated BMI reductions after 
a T2DM diagnosis are observed beyond year 1 and sustained over time. More specifically, we 
find statistically significant decreases of 1.089, 1.361, and 2.045 on the BMI scale for 1, 2, and 
3 years after the T2DM diagnosis, respectively. This appears to imply that the health 
information included in a T2DM diagnosis might not just have a statistically significant casual 
impact in the short-term but that it can also have a longer-term impact on BMI reduction. Such 
sustained causal impact also appears to increase over time with the largest reduction in BMI 
occurring three years after the diagnosis. This may be the result of a cumulated effect driven 
by consistent weight losses throughout the years for diagnosed patients.  
While this finding might be interesting, we may need to consider that it could be also partly 
caused by a selection process among patients in our sample. This is because estimates from 
model (6) are produced using a sample of patients presenting at least four consecutive BMI 
measurements, thus potentially including more conscientious individuals who might be more 
aware of the health consequences of their condition. Conversely, those who are excluded from 
the sample may include individuals who are less conscientious or less prone to follow up on 
their health status. However, such findings are among the first to present causal evidence on 
the long-term impact of a T2DM diagnosis on BMI.  
 
[TABLE 11 AROUND HERE] 
5. Conclusions 
This study provides new evidence on short- and long-term causal impacts of a diagnosis of 
type-2 diabetes mellitus (T2DM) on key modifiable lifestyle behaviours.  In order to identify 
                                                 
15 Note that we estimate Equation (6) on the sample of recently diagnosed individuals. We chose to do so as 
the identification of the long-term impacts on lifestyle behaviours using the more general sample of patients 
(including individuals with longer time elapsed from a T2DM diagnosis) might be confounded by other factors. 
For example, patients with earlier T2DM diagnoses are more likely to have developed further comorbidities or to 
have experienced additional treatments. Accordingly, this might have an impact on their weight loss over and 
above the one of a T2DM diagnosis. Indeed, estimates of long-term impacts produced using the general sample 
appear to confirm this as they present quantitatively larger effects (these are available upon request).            
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causal impacts, we exploit the exogenous cut-off of blood sugar in the diagnosis of T2DM 
provided by a reliable and accurate biomarker (HbA1c) via a fuzzy RDD and measure its 
impact on objectively measured BMI, quitting smoking and quitting drinking. This builds on 
and directly extends the emerging economics literature on the causal effects of health 
information on lifestyle behaviours by focusing on T2DM, a major public health concern 
whose prevalence is projected to increase worldwide. Importantly, we make use of 
comprehensive longitudinal medical records from Spain, including a number of diagnosed 
health conditions and relevant sociodemographic variables. This allows identifying long-term 
impacts as well as exploring heterogeneity in the impact of a diagnosis.  
We find a substantial reduction in body weight as a response to a T2DM diagnosis with 
larger short-term effects among patients who are obese and were diagnosed with depression. 
Short-term weight reductions appear to be more substantial also among women and middle-
aged individuals. Differently from most previous correlational studies, we provide evidence of 
statistically significant long-term impacts of a T2DM diagnosis on BMI up to three years from 
the diagnosis. Our results are robust to a series of robustness checks, including parametric 
estimations with different polynomials orders, as well as non-parametric estimations with 
several bandwidths.  
Interestingly, we also find that patients who are younger, still in the labour market and 
healthier also present increased short-term probabilities of quitting smoking. However, we 
should keep in mind that our data are not capable of capturing the intensive margin of smoking 
(or drinking), and so we cannot observe whether individuals diagnosed with T2DM would 
eventually reduce the daily number of cigarettes smoked or units of alcohol. It is also worth 
noting that our paper employs administrative data including individuals seeking medical advice 
at some point during the period examined in our analysis. As such, these patients might have 
been already advised to either losing weight or quitting alcohol and smoking before a potential 
T2DM diagnosis. Thus, our estimates might represent a lower band of the true impact of a 
T2DM diagnosis on lifestyle behaviours. Yet, this might not be necessarily the case for the 
long-term effects identified for BMI, as the sample used for the corresponding RDD models 
might include more conscientious patients who are more prone to follow up their condition.     
Our study has some potential limitations. Firstly, although our data includes a measure of 
employment status, as in most administrative datasets, specific information on education and 
income is not directly available, therefore limiting the scope of our heterogeneity analysis. 
Secondly, the lack of information on the specific medications prescribed to patients, prevents 
us from controlling for their potential effects. Despite such limitations, our paper offers novel 
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causal evidence on the impact of the health information provided by a T2DM diagnosis on key 
lifestyle behaviours both in the short-term and over time.  
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Tables and Figures










T2DM Diagnosis [0,1] -0.124 0.086 -0.325
(0.550) (0.060) (0.364)
Observations 13852 4220 687
Note: The Table reports RDD estimates on the outcomes of interest, when using a placebo cut-off. The
alternative cut-off value is 4.75 (%), for which no effects should be observed. Although not shown in the
Table, estimates are conditional on a set of covariates, time, areas and GP fixed effects (FE). Robust
standard errors are clustered on the running variable. * p < 0.1, ** p < 0.05, *** p < 0.01.
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Table 2: Summary Statistics
Mean S.D. Min Max Obs
Lifestyle Behaviours:
Body Mass Index 30.29 5.05 14 68 27920
Smoking [0,1] 0.18 0.38 0 1 39688
Drinking [0,1] 0.03 0.17 0 1 39688
T2DM Variables:
T2DM Diagnosis [0,1] 0.67 0.47 0 1 39688
Onset of T2DM 3.13 3.72 0 39 34741
HbA1C (%) 6.60 1.43 0 20 39994
Demographics:
Years of Age 65.10 12.62 16 106 39688
Female [0,1] 0.52 0.50 0 1 39688
Not Living Alone [0,1] 0.87 0.33 0 1 39688
Active [0,1] 0.27 0.44 0 1 39594
Immigrant [0,1l 0.02 0.13 0 1 39688
Other Conditions:
Hypertension [0,1] 0.59 0.49 0 1 39688
Dyslipedimia [0,1] 0.53 0.50 0 1 39688
Depression [0,1] 0.18 0.38 0 1 39688
Years:
2004 0.11 0.31 0 1 39994
2005 0.12 0.32 0 1 39994
2006 0.13 0.34 0 1 39994
2007 0.14 0.35 0 1 39994
2008 0.15 0.36 0 1 39994
2009 0.17 0.37 0 1 39994
2010 0.18 0.39 0 1 39994
Observations 39994
Note: The Table reports summary statistics of the main variables of interest.
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Figure 1: Continuity Test
Note: The Figure shows local polynomial estimates of a number of covariates as a function of the running
variable.
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Figure 2: Density of the Running variable
Note: The Figure shows evidence of no manipulation of the running variable. Bin size = 0.1. The bin





















































































Table 3: RDD Estimates of a T2DM Diagnosis











Above [0,1] 0.196*** 0.110*** 0.076*** 0.070*** 0.065***
(0.032) (0.025) (0.022) (0.023) (0.022)
Above * HbA1c -0.236*** -0.162*** -0.184*** -0.203*** -0.199***
(0.025) (0.017) (0.017) (0.020) (0.019)
Running Variable:
HbA1c (%) 0.247*** 0.163*** 0.184*** 0.200*** 0.196***
(0.025) (0.017) (0.017) (0.020) (0.018)
Attributes:
Years of Age -0.004*** -0.004*** -0.002*** -0.002***
(0.000) (0.000) (0.000) (0.000)
Female [0,1] -0.040*** -0.037*** -0.039*** -0.039***
(0.005) (0.007) (0.006) (0.006)
Not Living Alone [0,1] -0.021*** -0.027*** -0.021*** -0.023***
(0.005) (0.006) (0.006) (0.006)
Active [0,1] -0.076*** -0.074*** -0.013** -0.012*
(0.007) (0.007) (0.006) (0.006)
Immigrant [0,1l -0.069*** -0.070*** -0.027 -0.037*
(0.018) (0.024) (0.021) (0.021)
Onset of T2DM 0.066*** 0.063*** 0.073*** 0.073***
(0.006) (0.006) (0.005) (0.005)
Pre-existing Conditions:
Hypertension [0,1] 0.084*** 0.064*** 0.042*** 0.040***
(0.005) (0.005) (0.005) (0.005)
Dyslipedimia [0,1] 0.055*** 0.051*** 0.034*** 0.036***
(0.003) (0.005) (0.004) (0.004)
Depression [0,1] -0.017*** -0.018*** -0.015*** -0.012**
(0.005) (0.006) (0.005) (0.005)
Baseline Lifestyle:
BMI -0.000 0.001 0.001
(0.001) (0.001) (0.001)
Smoking -0.000 0.008 0.009
(0.006) (0.006) (0.006)
Drinking -0.027** -0.015 -0.010
(0.012) (0.011) (0.011)
Time FE X X
Area FE X X
GP FE X
Observations 39688 34359 24211 24209 24182
Note: The Table reports RDD estimates of a T2DM diagnosis. Although not shown in the Table, the
presented estimates are conditional on time, area, and GP fixed effects. Robust standard errors are
clustered on the running variable. * p < 0.1, ** p < 0.05, *** p < 0.01.
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T2DM Diagnosis [0,1] -1.013*** 0.014 -0.095
(0.166) (0.015) (0.075)
Running Variable:
HbA1c (%) 0.019 -0.000 0.001
(0.017) (0.001) (0.006)
Attributes:
Years of Age -0.009*** 0.000 -0.001
(0.002) (0.000) (0.001)
Female [0,1] -0.042* -0.005 -0.020
(0.023) (0.006) (0.035)
Not Living Alone [0,1] -0.043 0.004 0.015
(0.037) (0.006) (0.036)
Active [0,1] -0.072* -0.002 0.003
(0.042) (0.005) (0.036)
Immigrant [0,1l 0.303* -0.003 -0.299
(0.178) (0.027) (0.225)
Onset of T2DM 0.072*** -0.002 0.011
(0.013) (0.001) (0.008)
Pre-existing Conditions:
Hypertension [0,1] 0.062** -0.007 0.029
(0.027) (0.005) (0.021)
Dyslipedimia [0,1] 0.072*** -0.003 -0.007
(0.021) (0.006) (0.022)
Depression [0,1] 0.032 -0.001 0.046
(0.035) (0.005) (0.035)
Baseline Lifestyle:
BMI 0.968*** -0.000 0.000
(0.003) (0.000) (0.003)
Smoking 0.046 - -0.041**
(0.037) (-) (0.019)
Drinking 0.163** -0.003 -
(0.073) (0.007) (-)
Time FE X X X
Area FE X X X
GP FE X X X
Observations 13852 4220 687
Note: The Table reports RDD estimates of the impact of a T2DM diagnosis on lifestyle behaviours. Al-
though not shown in the Table, estimates are conditional on time, areas and GP fixed effects. Robust
standard errors are clustered on the running variable. * p < 0.1, ** p < 0.05, *** p < 0.01.
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T2DM Diagnosis [0,1] -1.140*** 0.058**
(0.346) (0.023)
Observations 2730 1842
Out of the Labour Force:
T2DM Diagnosis [0,1] -0.955*** -0.031
(0.197) (0.026)
Observations 11122 2378
Note: The Table reports RDD estimates of the impact of a T2DM diagnosis on lifestyle behaviours. Al-
though not shown in the Table, estimates are conditional on a set of covariates, as described in Section
4, as well as time, areas and GP fixed effects (FE). Robust standard errors are clustered on the running
variable. * p < 0.1, ** p < 0.05, *** p < 0.01.
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T2DM Diagnosis [0,1] -0.973* -0.051
(0.569) (0.060)
Observations 2196 501
Note: The Table reports RDD estimates of the impact of a T2DM diagnosis on lifestyle behaviours. Fol-
lowing the WHO classification, an individual with a BMI between 18.50 and 24.99 is considered to have
a healthy weight; an individual with a BMI between 25 and 29.99 is considered overweight; an individual
with a BMI equals to or greater than 30 is considered obese; and an individual with a BMI equals to
or greater than 35 is considered severely obese. Although not shown in the Table, estimates are condi-
tional on a set of covariates, as described in Section 4, as well as on time, area and GP fixed effects (FE).
Robust standard errors are clustered on the running variable. * p < 0.1, ** p < 0.05, *** p < 0.01.
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T2DM Diagnosis [0,1] -1.850*** 0.009
(0.585) (0.049)
Observations 2305 609
Note: The Table reports RDD estimates of the impact of a T2DM diagnosis on lifestyle behaviours. Al-
though not shown in the Table, estimates are conditional on a set of covariates as described in Section
4, as well as time, areas and GP fixed effects (FE). Robust standard errors are clustered on the running
variable. * p < 0.1, ** p < 0.05, *** p < 0.01.
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T2DM Diagnosis [0,1] -1.013*** 0.014 -0.095
(0.166) (0.015) (0.075)
Observations 13852 4220 687
Panel B: Bandwidth = 2
T2DM Diagnosis [0,1] -0.716*** 0.026 -0.013
(0.166) (0.020) (0.082)
Observations 12621 3687 604
Panel C: Bandwidth = 1.75
T2DM Diagnosis [0,1] -0.688*** 0.012 -0.115
(0.172) (0.024) (0.130)
Observations 12115 3475 562
Panel D: Bandwidth = 1.5
T2DM Diagnosis [0,1] -0.709*** 0.020 -0.091
(0.211) (0.026) (0.154)
Observations 11546 3302 525
Panel E: Bandwidth = 1.25
T2DM Diagnosis [0,1] -0.742*** -0.011 -0.060
(0.271) (0.037) (0.115)
Observations 10298 2924 465
Panel E: Bandwidth = 1
T2DM Diagnosis [0,1] -0.645** 0.049 0.081
(0.280) (0.034) (0.107)
Observations 9258 2584 414
Note: The Table reports non-parametric RDD estimates of the impact of a T2DM diagnosis on lifestyle
behaviours. Each coefficient in the table report the effect of being diagnosed with T2DM on lifestyle be-
haviours. Although not shown in the Table, estimates are conditional on a set of covariates, as described
in Section 4, as well as time, areas and GP fixed effects (FE). Robust standard errors are clustered on
the running variable. * p < 0.1, ** p < 0.05, *** p < 0.01.
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T2DM Diagnosis [0,1] -1.013*** 0.014 -0.095
(0.166) (0.015) (0.075)
Observations 13852 4220 687
Panel B: Quadratic
T2DM Diagnosis [0,1] -1.087*** -0.006 -0.119
(0.246) (0.017) (0.106)
Observations 13852 4220 687
Panel C: Cubic
T2DM Diagnosis [0,1] -0.737*** -0.012 -0.050
(0.247) (0.018) (0.108)
Observations 13852 4220 687
Panel D: Quartic
T2DM Diagnosis [0,1] -0.710*** -0.018 0.037
(0.242) (0.021) (0.124)
Observations 13852 4220 687
Note: The Table reports RDD estimates of the impact of a T2DM diagnosis on lifestyle behaviours, when
considering different polynomials of the running variable. Although not shown in the Table, estimates
are conditional on a set of covariates, as described in Section 4, as well as time, areas and GP fixed effects
(FE). Robust standard errors are clustered on the running variable. * p < 0.1, ** p < 0.05, *** p < 0.01.
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T2DM Diagnosis -0.817** 0.107 -0.088
(0.365) (0.080) (0.108)
Running Variable:
HbA1c (%) 0.025 -0.007 0.004
(0.051) (0.008) (0.012)
Attributes:
Years of Age -0.011*** 0.001 -0.002
(0.004) (0.000) (0.002)
Female [0,1] -0.014 0.014* 0.044
(0.050) (0.009) (0.057)
Not Living Alone [0,1] 0.023 0.000 -0.014
(0.093) (0.007) (0.035)
Active [0,1] -0.109 -0.006 0.005
(0.086) (0.007) (0.040)
Immigrant [0,1l 0.254 0.035 -0.434
(0.314) (0.043) (0.355)
Onset of T2DM 0.000 0.000 0.000
(.) (.) (.)
Pre-existing Conditions:
Hypertension [0,1] 0.082 -0.012 0.069**
(0.062) (0.008) (0.027)
Dyslipedimia [0,1] -0.019 -0.002 0.017
(0.048) (0.007) (0.035)
Depression [0,1] 0.001 -0.009 0.063
(0.064) (0.010) (0.055)
Baseline Lifestyle:
BMI 0.956*** -0.000 -0.003
(0.006) (0.001) (0.004)
Smoking 0.177** 0.000 -0.038
(0.090) (.) (0.031)
Drinking 0.271* -0.008 0.000
(0.149) (0.009) (.)
Observations 3266 1427 248
Note: The Table reports RDD estimates of the impact of a T2DM diagnosis on lifestyle behaviours, for
the sample of individuals not diagnosed at time t Although not shown in the Table, estimates are condi-
tional on a set of covariates, time, areas and GP fixed effects (FE). Robust standard errors are clustered
on the running variable. * p < 0.1, ** p < 0.05, *** p < 0.01.
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T2DM Diagnosis [0,1] -1.089** -1.361** -2.045***
(0.492) (0.556) (0.722)
Observations 1535 1210 899
Note: The Table reports RDD estimates of the long-term effect of a T2DM diagnosis on body mass in-
dex, for the sample of individuals not diagnosed at time t. Although not shown in the Table, estimates
are conditional on a set of covariates, time, areas and GP fixed effects (FE). Robust standard errors are
clustered on the running variable. * p < 0.1, ** p < 0.05, *** p < 0.01.
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Table A.1: Descriptive Statistics by Year
(1) (2) (3) (4) (5) (6) (7)
2004 2005 2006 2007 2008 2009 2010
Lifestyle Behaviours:
Body Mass Index 30.40 30.38 30.34 30.32 30.20 30.18 30.27
Smoking [0,1] 0.18 0.18 0.17 0.18 0.18 0.19 0.18
Drinking [0,1] 0.03 0.03 0.03 0.03 0.03 0.03 0.03
T2DM Variables:
T2DM Diagnosis [0,1] 0.75 0.75 0.71 0.71 0.69 0.62 0.56
Onset of T2DM 1.84 2.34 2.74 3.18 3.52 3.71 3.73
HbA1C (%) 6.72 6.46 6.57 6.39 6.37 6.72 6.85
Demographics:
Years of Age 63.38 64.02 64.80 64.98 65.77 65.80 65.95
Female [0,1] 0.54 0.53 0.54 0.52 0.51 0.51 0.51
Not Living Alone [0,1] 0.88 0.87 0.87 0.87 0.87 0.87 0.88
Active [0,1] 0.22 0.23 0.24 0.26 0.27 0.30 0.33
Immigrant [0,1l 0.01 0.01 0.01 0.01 0.02 0.02 0.02
Other Conditions:
Hypertension [0,1] 0.63 0.62 0.61 0.60 0.60 0.56 0.53
Dyslipedimia [0,1] 0.55 0.56 0.55 0.54 0.53 0.52 0.50
Depression [0,1] 0.18 0.18 0.18 0.18 0.18 0.17 0.17
Observations 4405 4769 5303 5551 5968 6638 7360
Note: The Table reports means and standard deviations of the main variables used in the paper.
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